Peptide Side Effects: Complete Guide to Every Major Peptide Class

All biologically active compounds — including peptides — have potential side effects. The peptide community often minimises these risks, but responsible research requires honest assessment of what can go wrong.

Side effects fall into three categories: 1. Mechanism-based: Predictable from the peptide's mode of action (e.g., GH peptides causing water retention) 2. Off-target: Effects on unintended receptors or pathways (e.g., Melanotan II causing nausea via central melanocortin receptors) 3. Administration-related: Injection site reactions, contamination effects

This guide organises side effects by peptide class for easy reference.

Important Context: Side effect data quality varies enormously. GLP-1 agonists (semaglutide, tirzepatide) have extensive Phase III trial data. Healing peptides (BPC-157, TB-500) have mostly animal data. The absence of reported side effects does NOT mean a peptide is safe — it may mean it hasn't been adequately studied.

These peptides elevate growth hormone, and most side effects are GH-mediated:

Common (>10% incidence): - Water retention / oedema (swollen hands, feet, face) - Joint stiffness - Tingling / numbness (paraesthesia) — especially in hands - Increased appetite (GHRP-6 and MK-677 in particular) - Vivid dreams / altered sleep patterns

Less Common (1-10%): - Carpal tunnel syndrome symptoms - Mild headache - Transient blood glucose elevation - Injection site reactions (redness, itching)

Rare but Important (<1%): - Insulin resistance (particularly MK-677 with chronic use) - Elevated cortisol (GHRP-2, GHRP-6 — NOT Ipamorelin) - Elevated prolactin (GHRP-2 specifically) - Theoretical cancer risk with chronic IGF-1 elevation

Class-Specific Notes: - Ipamorelin has the cleanest profile: GH-selective with no cortisol/prolactin elevation - MK-677 has the most side effects due to sustained 24-hour GH elevation and strong ghrelin activation - GHRP-6 causes the most appetite stimulation - CJC-1295 with DAC causes prolonged side effects due to 8-day half-life

These are the best-studied peptides with extensive Phase III trial data:

Very Common (>20%): - Nausea (especially during dose titration — typically improves over 4-8 weeks) - Diarrhoea - Constipation - Abdominal pain - Decreased appetite (therapeutic effect, but can be excessive)

Common (5-20%): - Vomiting - Fatigue - Headache - Dyspepsia (indigestion) - Injection site reactions

Less Common but Important: - Gastroparesis: Delayed gastric emptying can become clinically significant - Gallbladder issues: Increased gallstone risk, especially with rapid weight loss - Pancreatitis: Rare but FDA black box warning. Discontinue if severe abdominal pain occurs - Muscle loss: Weight loss includes lean mass (20-40% of weight lost may be muscle)

Rare Concerns: - Thyroid C-cell tumours (observed in rodents, relevance to humans uncertain — FDA warning) - Acute kidney injury (usually secondary to dehydration from vomiting) - Suicidal ideation (under investigation — European review ongoing) - Intestinal obstruction (rare case reports)

Management Strategies: - Slow dose titration (start low, increase gradually over 4-8 weeks) - Small, frequent meals - Avoid high-fat and high-sugar foods - Stay well-hydrated - Resistance training to preserve muscle mass - Consider protein supplementation (1.2-1.6 g/kg/day)

Healing Peptides (BPC-157, TB-500): ⚠️ Important caveat: Most safety data is from animal studies

*Reported in animal studies and anecdotal human reports:* - Injection site reactions (redness, swelling) - Mild nausea (BPC-157, particularly with oral dosing) - Headache - Dizziness - Fatigue

*Theoretical concerns:* - BPC-157 affects growth factor expression — theoretical angiogenesis concern in cancer patients - TB-500 promotes cell migration — theoretical concern in metastatic disease - Neither peptide has systematic human safety data

Nootropic Peptides (Semax, Selank): *From clinical use in Russia (thousands of patients):* - Generally well-tolerated - Nasal irritation (intranasal route) - Mild headache - Semax: rare reports of anxiety or irritability at high doses - Selank: sedation or drowsiness possible - No serious adverse effects in published clinical data

Cosmetic Peptides (Argireline, Matrixyl, GHK-Cu, SNAP-8): - Topical application — systemic side effects are essentially absent - Local skin irritation, redness, or sensitivity (rare) - Contact dermatitis (very rare, typically preservative-related) - These are among the safest peptide categories due to topical-only use

Immune Peptides (Thymosin Alpha-1, LL-37): - Thymosin Alpha-1: injection site reactions, rare flu-like symptoms - LL-37: antimicrobial — theoretical concern about antimicrobial resistance with chronic use - KPV: minimal side effect data available

General Injection-Related Side Effects (All Injectable Peptides): - Injection site pain, redness, bruising - Lipodystrophy (tissue changes with repeated injections at same site) - Infection risk (poor sterile technique) - Allergic reaction (rare) - Contamination effects (unregulated products may contain endotoxins, heavy metals, or degradation products)

Disclaimer: This guide is for educational purposes only. Side effect profiles may be incomplete due to limited human research for many peptides. Always consult healthcare professionals and report adverse effects.